Andrew Cleeland

Andrew Cleeland is an accomplished professional with a solid academic background, having studied Biophysics at Swinburne University of Technology.

He has an extensive history of leadership roles in various prestigious organizations, showcasing his expertise in the medical and healthcare industry.

Andrew has held key positions such as Director and Chairman on the Board of Directors at leading companies like Francis Medical, atHeart Medical, and MMI S.p.A.

His contributions extend to associations like the Medical Device Innovation Consortium (MDIC) and A*STAR - Agency for Science, Technology and Research in Singapore.

Andrew Cleeland's experience also includes advisory roles at notable firms such as Longitude Capital, Arboretum Ventures, and UCSF-Stanford Pediatric Device Consortium.

He has excelled in executive positions like CEO at Fogarty Innovation, President and CEO at Twelve, Inc. and Ardian, Inc., and Vice President at companies like Medtronic and Radiant Medical.

Furthermore, Andrew has demonstrated his regulatory expertise through roles like Director of RA/CA at Baxter Healthcare and Reg Affairs at Telectronics Pacing Systems.

His diverse professional journey encompasses strategic roles in companies like Saluda Medical, nVision Medical, and Zenflow, Inc., reflecting his strong acumen in the healthcare and biomedical sectors.